氟尼辛葡甲胺

Chemistry - Flunixin meglumine, a nonsteroidal anti-inflammatory agent that is a highly substituted derivative of nicotinic acid, is unique structurally when compared to other NSAIDs. The chemical name for flunixin is 3-pyridine-carboxylic acid.

Storage/Stability/Compatibility - All flunixin products should be stored between 2-30°C (36-86°F). It has been recommended that flunixin meglumine injection not be mixed with other drugs because of unknown compatibilities.

Pharmacology - Flunixin is a very potent inhibitor of cyclooxygenase and like other NSAIDs, it exhibits analgesic, anti-inflammatory and antipyrexic activity. Flunixin does not appreciably alter GI motility in horses and may improve hemodynamics in animals with septic shock.

Pharmacokinetics - In the horse, flunixin is rapidly absorbed following oral administration with an average bioavailability of 80% and peak serum levels in 30 minutes. The onset of action is generally within 2 hours; peak response occurs between 12-16 hours and the duration of action lasts up to 36 hours. It is unknown how extensively flunixin is bound to plasma proteins or where it distributes in the body. It is unclear if the drug is extensively metabolized and exactly how the drug is removed from the body. Serum half-lives have been determined in horses ≈ 1.6 hours, dogs ≈ 3.7 hours; cattle ≈ 8.1 hours. Flunixin is detectable in equine urine for at least 48 hrs. after a dose.

Uses/Indications - In the United States, flunixin meglumine is approved for use in horses and cattle. However, it is approved for use in dogs in other countries. The approved indications for its use in the horse are for the alleviation of inflammation and pain associated with musculoskeletal disorders and alleviation of visceral pain associated with colic in the horse. In cattle it is approved for the control of pyrexia associated with bovine respiratory disease and endotoxemia, and for the control of inflammation in endotoxemia.

Flunixin has been touted for many other indications in various species, including: Horses: foal diarrheas, shock, colitis, respiratory disease, post-race treatment, and pre- and post ophthalmic and general surgery; Dogs: disk problems, arthritis, heat stroke, diarrhea, shock, ophthalmic inflammatory conditions, pre- and post ophthalmic and general surgery, and treatment of parvovirus infection; Cattle: acute respiratory disease, acute coliform mastitis with endotoxic shock, pain (downer cow), and calf diarrheas; Swine: agalactia/hypogalactia, lameness, and piglet diarrhea. It should be noted that the evidence supporting some of these indications is equivocal and flunixin may not be appropriate for every case.